LMR Partners LLP Sells 1,411 Shares of Repligen Co. (NASDAQ:RGEN)

LMR Partners LLP decreased its holdings in Repligen Co. (NASDAQ:RGEN) by 5.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,756 shares of the biotechnology company’s stock after selling 1,411 shares during the period. LMR Partners LLP’s holdings in Repligen were worth $3,275,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Signaturefd LLC boosted its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. bought a new position in shares of Repligen during the fourth quarter worth $29,000. Itau Unibanco Holding S.A. purchased a new position in Repligen during the fourth quarter valued at $40,000. UMB Bank n.a. increased its holdings in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. Finally, Global Retirement Partners LLC lifted its stake in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 129 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 8.5%

Shares of NASDAQ RGEN opened at $133.72 on Tuesday. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The firm has a 50-day simple moving average of $134.55 and a two-hundred day simple moving average of $145.43. The company has a market cap of $7.51 billion, a P/E ratio of -262.20, a PEG ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. During the same quarter in the previous year, the business earned $0.28 EPS. Repligen’s revenue was up 10.4% compared to the same quarter last year. Research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on RGEN shares. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Thursday, May 8th. Canaccord Genuity Group reduced their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. TD Cowen started coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. Royal Bank of Canada cut their target price on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating for the company in a report on Wednesday, April 30th. Finally, Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target on the stock. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $173.25.

Insider Activity at Repligen

In other news, Director Margaret Pax bought 250 shares of the stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.